Skip to main content
. Author manuscript; available in PMC: 2015 Dec 23.
Published in final edited form as: Chem Rev. 2015 Jul 8;115(19):11109–11146. doi: 10.1021/acs.chemrev.5b00109

Figure 9.

Figure 9

Nanoparticles targeted to lung DCs enhance vaccine uptake and protect against infection challenge. (A & B) C57BL/6 mice were immunized intratracheally with OVA in lipid nanoparticle (ICMV) or soluble formulations. Representative cryosections after intratracheal immunization with fluorescent OVA (red) from lungs on day 1 (A; scale bars, 50 µm) and mediastinal draining lymph nodes (mdLNs) on day 4 (B; scale bars, 200 µm). (C) C57BL/6 mice were immunized intratracheally or subcutaneously with a peptide vaccine in nanoparticle (ICMV) or soluble forms on days 0 and 28, then challenged by intratracheal administration of vaccinia virus (1×106 PFU) on day 42; body weight changes were tracked over time. Adapted from Li et al.169 Reprinted with permission from reference 169. Copyright 2013 American Association for the Advancement of Science.